Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.86 |
| ▸ | FNTB | P49356 | 5/20 | 0.86 |
| ▸ | TSHR | P16473 | 4/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | AR | P10275 | 2/20 | 0.81 |
| ▸ | BLM | P54132 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | SHBG | P04278 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.73 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4105697 | 0.91 | FNTA (0.85) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL31249833 | 0.91 | FNTA (0.82) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL2963066 | 0.90 | FNTA (0.81) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL31249685 | 0.90 | FNTA (0.81) | FNTAFNTBTSHRNR3C1KMT2A | |
| Hydrochloric Acid SCHEMBL31249712 | 0.90 | FNTA (0.81) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL9819561 | 0.89 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL4501 | 0.89 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL10301195 | 0.89 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL9819556 | 0.89 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A | |
| Hydrochloric Acid SCHEMBL31249874 | 0.89 | FNTA (0.79) | FNTAFNTBTSHRNR3C1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108301244-A | A kind of compounding method of the short hair snow Neil ground cushion of super-strong moisture absorbing euchroic | 金华洁灵家居用品有限公司 | 2018-07-20 | — | — | CN | claimed |
| CN-108285889-A | For mescenchymal stem cell（MSC）The molecular combinations of external adhere-wall culture amplification and application | 北京三有利生物技术有限公司 | 2018-07-17 | — | — | CN | claimed |
| US-5236906-A | Adrenocortical hormone and hyaluronic acid; skin diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-08-17 | — | — | US | claimed |
| US-20240376164-A1 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY CAUSED BY ND4 MUTATION | Wuhan Neurophth Biotechnology Limited Company (CN) | 2024-11-14 | — | — | US | disclosed |
| EP-4382601-A1 | COMPOSITION AND METHOD FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY CAUSED BY ND4 MUTATION | Wuhan Neurophth Biotechnology Limited Company (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-115315261-A | Methods of treating respiratory diseases, disorders or conditions caused by viral infections | 索芙特海尔公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-113767115-A | Therapeutic interferon alpha 1 proteins | 奥里尼斯生物科学股份有限公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-112584874-A | Compositions and methods for treating leber's hereditary optic neuropathy | 武汉纽福斯生物科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112566934-A | B7-H4 antibodies and methods of use thereof | 奈斯科尔公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-108285889-A | For mescenchymal stem cell（MSC）The molecular combinations of external adhere-wall culture amplification and application | 北京三有利生物技术有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-106132400-A | Composition for treating ulcerative colitis | 希格默伊德药业有限公司 | 2016-11-16 | — | — | CN | disclosed |
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| WO-2009136976-A2 | IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF | AMGEN INC (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-0596876-A1 | CHELATOR COMPOSITIONS COMPRISING ALPHA-DIAMINE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1994-05-18 | — | — | EP | disclosed |
| US-5236906-A | Adrenocortical hormone and hyaluronic acid; skin diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-08-17 | — | — | US | disclosed |
| EP-0596876-A4 | CHELATOR COMPOSITIONS COMPRISING ALPHA-DIAMINE COMPOUNDS. | PROCTER & GAMBLE (US) | 1993-03-01 | — | — | EP | disclosed |
| EP-0504403-A1 | TOPICAL THERAPEUTIC PREPARATION | Takeda Chemical Industries, Ltd. (JP) | 1992-09-23 | — | — | EP | disclosed |
| WO-1991016035-A1 | CHELATOR COMPOSITIONS COMPRISING ALPHA-DIAMINE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1991-10-31 | — | — | WO | disclosed |
| WO-1991007974-A1 | TOPICAL THERAPEUTIC PREPARATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-13 | — | — | WO | disclosed |
| EP-0313305-A2 | Photoprotection compositions comprising chelating agents | THE PROCTER & GAMBLE COMPANY (US) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | FNTA 1097/4885FNTB 1918/4885TSHR 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.